Switching from natalizumab to alemtuzumab in patients with relapsing multiple sclerosis

被引：4
|
作者：
John, Nevin [1 ]
Carroll, Antonia [2 ]
Brownlee, Wallace J. [2 ,3 ]
Chataway, Jeremy [1 ,2 ]
机构：
[1] UCL, Inst Neurol, Neuroinflammat, London WC1N 3BG, England
[2] Univ Coll London Hosp NHS Fdn Trust, Natl Hosp Neurol & Neurosurg, London, England
[3] Queen Sq Multiple Sclerosis Ctr, Dept Neuroinflammat, London, England
来源：
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY | 2019年 / 90卷 / 12期
关键词：
FINGOLIMOD;
D O I：
10.1136/jnnp-2019-320687
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：1376 / +
页数：3
相关论文
共 50 条
  • [31] Natalizumab for relapsing-remitting multiple sclerosis
    Horga, A.
    Tintore, M.
    NEUROLOGIA, 2011, 26 (06): : 357 - 368
  • [32] Natalizumab (Tysabri) treatment for relapsing multiple sclerosis
    Johnson, Kenneth P.
    NEUROLOGIST, 2007, 13 (04) : 182 - 187
  • [33] Alemtuzumab: A Review in Relapsing Remitting Multiple Sclerosis
    Yahiya Y. Syed
    Drugs, 2021, 81 : 157 - 168
  • [34] Alemtuzumab: A Review in Relapsing Remitting Multiple Sclerosis
    Syed, Yahiya Y.
    DRUGS, 2021, 81 (01) : 157 - 168
  • [35] Natalizumab for relapsing multiple sclerosis - The editorialist replies
    Ropper, AH
    NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (22): : 2389 - 2389
  • [36] Natalizumab reduces loss of visual function in patients with relapsing multiple sclerosis
    Balcer, L
    Galetta, SL
    O'Connor, PW
    Havrdova, E
    Hutchinson, M
    Kappos, L
    Miller, DH
    Phillips, JT
    Polman, CH
    Stuart, WH
    Calabresi, PA
    Confavreux, C
    Radue, EW
    Rudick, RA
    Lublin, FD
    Giovannoni, G
    Wajgt, A
    Weinstock-Guttman, B
    Wynn, DR
    Lynn, FA
    Panzara, MA
    Sandrock, AW
    NEUROLOGY, 2006, 66 (05) : A251 - A251
  • [37] Retrospective analysis of natalizumab switches to ublituximab in patients with relapsing multiple sclerosis
    Kutz, Christen
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 1074 - 1075
  • [38] Autoimmunity in patients treated with alemtuzumab for relapsing-remitting multiple sclerosis
    Fox, E. J.
    Arnold, D. L.
    Cohen, J.
    Coles, A. J.
    Confavreux, C.
    Hartung, H. -P.
    Havrdova, E.
    Selmaj, K.
    Weiner, H.
    Lake, S. L.
    Margolin, D. H.
    Oyuela, P.
    Panzara, M.
    Compston, D. A. S.
    MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 465 - 466
  • [39] Characteristics of PML cases in multiple sclerosis patients switching to fingolimod from natalizumab
    Putzki, N.
    Clifford, D. B.
    Bischof, D.
    Moore, A.
    Weinshenker, B. G.
    Freedman, M. S.
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 : 43 - 43
  • [40] The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM
    Havrdova, E
    O'Connor, P
    Hutchinson, M
    Kappos, L
    Miller, D
    Phillips, JT
    Polman, C
    Lublin, F
    Giovannoni, G
    Wajgt, A
    Lynn, F
    Toal, M
    Panzara, M
    Sandrock, A
    JOURNAL OF NEUROLOGY, 2005, 252 : 46 - 46
12345